These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37468530)

  • 21. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
    López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
    Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nirsevimab: A Review.
    Balbi H
    Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDC changes recommendations due to severe nirsevimab shortage during the 2023-2024 RSV season.
    Rahmat ZS; Ahmad S; Malikzai A
    Pediatr Pulmonol; 2024 Apr; 59(4):1108-1109. PubMed ID: 38240360
    [No Abstract]   [Full Text] [Related]  

  • 26. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in
    Pisuttinusart N; Rattanapisit K; Srisaowakarn C; Thitithanyanont A; Strasser R; Shanmugaraj B; Phoolcharoen W
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327142. PubMed ID: 38508690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?].
    Novoa Pizarro JM; Lindemann Tappert BC; Luchsinger Farías VR; Vargas Munita SL
    Andes Pediatr; 2023 Dec; 94(6):672-680. PubMed ID: 38329302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First RSV epidemic with nirsevimab. Older children than previous epidemics, even when hospitalized.
    Cantais A; Annino N; Thuiller C; Tripodi L; Cesana P; Seigle-Ferrand E; Zekre F; Pillet S; Pozzetto B
    J Med Virol; 2024 Feb; 96(2):e29483. PubMed ID: 38375933
    [No Abstract]   [Full Text] [Related]  

  • 30. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.
    Alharbi A; Yousef A; Zubani A; Alzahrani M; Al-Hindi M; Alharbi S; Alahmadi T; Alabdulkarim H; Kazmierska P; Beuvelet M
    Adv Ther; 2024 Apr; 41(4):1419-1435. PubMed ID: 38356106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
    Turalde-Mapili MWR; Mapili JAL; Turalde CWR; Pagcatipunan MR
    Front Pediatr; 2023; 11():1132740. PubMed ID: 37082704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
    Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
    Front Immunol; 2021; 12():708939. PubMed ID: 34456918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
    Sanders SL; Agwan S; Hassan M; van Driel ML; Del Mar CB
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009417. PubMed ID: 31446622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants.
    Simões EAF; Forleo-Neto E; Geba GP; Kamal M; Yang F; Cicirello H; Houghton MR; Rideman R; Zhao Q; Benvin SL; Hawes A; Fuller ED; Wloga E; Pizarro JMN; Munoz FM; Rush SA; McLellan JS; Lipsich L; Stahl N; Yancopoulos GD; Weinreich DM; Kyratsous CA; Sivapalasingam S
    Clin Infect Dis; 2021 Dec; 73(11):e4400-e4408. PubMed ID: 32897368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.
    Fullarton J; Keary I; Paes B; Tarride JE; Carbonell-Estrany X; Rodgers-Gray B
    J Infect Dis; 2023 May; 227(11):1333-1334. PubMed ID: 36520978
    [No Abstract]   [Full Text] [Related]  

  • 37. Nirsevimab reduces medically attended RSV-associated lower respiratory tract infection and hospitalisations in healthy pre-term infants.
    Murphy S
    Arch Dis Child Educ Pract Ed; 2022 Aug; 107(4):310-311. PubMed ID: 33597216
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.
    Sun BW; Zhang PP; Wang ZH; Yao X; He ML; Bai RT; Che H; Lin J; Xie T; Hui Z; Ye XY; Wang LW
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
    Choi SH; Park KS; Kim YJ
    J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
    Gomez GB; Nelson CB; Rizzo C; Shepard DS; Chaves SS
    J Infect Dis; 2022 Aug; 226(Suppl 2):S293-S299. PubMed ID: 35968865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.